Synergy Effects of HPV E6-E7 Encoding mRNA and Nucleic Acid Immunostimulators Improve Therapeutic Potential in TC-1...

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Cervical cancer, a global health concern, is primarily caused by human papillomavirus (HPV) infection.
• Messenger RNA (mRNA) vaccines offer a scalable platform for therapeutic applications, including potential antitumor effects against HPV.
• Developing effective therapeutic vaccines for HPV-induced cancers remains a critical challenge.

Purpose of the Study:

• To develop and evaluate a novel mRNA vaccine platform for cervical cancer.
• To assess the immunogenicity and antitumor efficacy of an mRNA vaccine encoding HPV E6 and E7 proteins encapsulated in lipid nanoparticles (LNPs) with immunostimulators (CPG 1018).

Main Methods:

• Development of an LNP-CPG 1018 mRNA vaccine platform encapsulating HPV E6-E7 mRNA.
• In vitro assessment of bone marrow-derived dendritic cell (BMDC) maturation.
• In vivo evaluation of vaccine efficacy in TC-1 tumor-bearing mice, including immune response and tumor growth inhibition.

Main Results:

• The LNP-CPG 1018 mRNA vaccine significantly promoted BMDC maturation in vitro.
• The vaccine demonstrated efficient migration to lymph nodes in vivo.
• Subcutaneous immunization in tumor-bearing mice elicited robust tumor-specific T-cell immunity, reshaped the tumor microenvironment, and inhibited tumor growth.

Conclusions:

• The LNP-CPG 1018 system serves as a promising delivery platform for mRNA-based cancer vaccines.
• This platform facilitates the development of effective therapeutic vaccines against HPV-induced cancers.
• The study highlights the potential of mRNA vaccines in combating cervical cancer.